Clinical Nuclear Medicine最新文献

{"title":"[18F]FDG PET-CT in Weber-Christian Disease.","authors":"Vicky Betech-Antar, Miguel Barrio-Piqueras, Juan J Rosales, Inmaculada Colina, Macarena Rodriguez-Fraile","doi":"10.1097/RLU.0000000000005713","DOIUrl":"10.1097/RLU.0000000000005713","url":null,"abstract":"<p><p>A 46-year-old woman with relapsing fever and painful pelvic subcutaneous nodules was referred to our center for a second opinion. Despite antibiotic and corticoid treatment, inflammation markers remained high. FDG-PET/CT was performed to evaluate the possible cause of her clinical condition, exclude systemic disease and evaluate the extension and inflammation of the nodules. FDG-PET/CT showed multiple abdominopelvic subcutaneous soft tissue foci without visceral involvement. The review of a previous nodule biopsy revealed Weber-Christian Disease (WCD), a rare disorder characterized by idiopathic nodular panniculitis, fever, and systemic inflammation. WCD is a diagnosis of exclusion when no other cause of panniculitis can be identified.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 5","pages":"e303-e304"},"PeriodicalIF":9.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143778986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rosai-Dorfman Disease Mimicking Metastasis to the Spleen From Breast Cancer.","authors":"Zamaan Hooda, Yang Lu, Reza John Mehran, Cesar Moran, Carlos Hernando Barcenas","doi":"10.1097/RLU.0000000000005796","DOIUrl":"10.1097/RLU.0000000000005796","url":null,"abstract":"<p><p>Rosai-Dorfman disease is a non-Langerhans cell histiocytosis with ubiquitous distribution. Although more common in lymph nodes, it has been described in many organ systems. The current case depicts a 54-year-old woman with a history of estrogen receptor-positive breast carcinoma who showed different image features of metastatic lymph nodes and splenic Rosai-Dorfman disease on FDG and FES PET/CT scans.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 5","pages":"450-451"},"PeriodicalIF":9.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significant 99mTc-FAPI-46 Uptake in 2 Cases of TENIS Syndrome With Negative Tc-OCTREOTIDE Scan, a New Hope in Theranostic Applications.","authors":"Mitra Ghahraman, Kamran Aryana, Seyed Rasoul Zakavi, Farivash Karamian, Atena Aghaee","doi":"10.1097/RLU.0000000000005817","DOIUrl":"10.1097/RLU.0000000000005817","url":null,"abstract":"<p><p>The role of fibroblast activation protein inhibitor (FAPI) as a novel radiopharmaceutical in the field of cancer diagnosis and treatment (theranostic) is still under investigation. We present 2 patients of differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy (TENIS syndrome) who underwent 99mTc-OCTREOTIDE scan and 99mTc-FAPI SPECT/CT to evaluate possible sites for metastasis. 99mTc-OCTREOTIDE scan showed no remarkable uptake in these patients. On the other hand, foci of metastatic disease were found, with intense 99mTc-FAPI-46 uptake. Malignant FAPI uptake was evident in the lungs, liver, adrenal, and abdominal lymph nodes in a patient and in the lungs of another one. Due to proper uptake in diagnostic scans, these patients were recognized as a suitable candidate for treatment with 177Lu-FAPI-46.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 5","pages":"e290-e291"},"PeriodicalIF":9.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ectopic Right Kidney Imaged With Dynamic 82Rb PET/CT.","authors":"Nasir Gözlügöl, Hasan Sari, Ali Afshar-Oromieh, Axel Rominger, Federico Caobelli","doi":"10.1097/RLU.0000000000005716","DOIUrl":"10.1097/RLU.0000000000005716","url":null,"abstract":"<p><p>Ectopic kidney in the thoracic region are infrequent in clinical practice. A 64-year-old man underwent a Rubidium (82Rb) positron emission tomography/computed tomography (PET-CT) scan for the evaluation of myocardial ischemia due to a diagnosed 2-vessel coronary artery disease. While no myocardial perfusion abnormalities were detected, the scan showed the presence of a diaphragmatic high stand on the right side, with evidence of an ectopic kidney. We here present static and flow dynamic images of this rare finding1-3.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 5","pages":"e320-e321"},"PeriodicalIF":9.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Lesion Uptake of [ 177 Lu]Lu-DOTA-Rituximab in Skeletal and Splenic Disease in Diffuse Large B-Cell Lymphoma.","authors":"Yeshwanth Edamadaka, Rahul V Parghane, Sandip Basu","doi":"10.1097/RLU.0000000000005695","DOIUrl":"10.1097/RLU.0000000000005695","url":null,"abstract":"<p><strong>Abstract: </strong>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, and a sizable fraction of the DLBCL patients presents with advanced, relapsed, and refractory disease, demonstrating poor response to standard chemotherapy regimens. Radioimmunotherapy (RIT) has shown to be clinically effective in refractory DLBCL. We present the case of a patient with DLBCL with [ 18 F]FDG-avid widespread skeletal as well as splenic involvement as poor prognostic extranodal disease on FDG PET/CT. RIT based on [ 177 Lu]Lu-DOTA-rituximab was explored to study the biodistribution and dosimetry of [ 177 Lu]Lu-DOTA-rituximab in CD20-positive lymphoma. An exceptionally high tracer concentration in skeletal and splenic disease was observed, supporting its potential RIT application in relapsed and refractory DLBCL patients in the future.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e292-e293"},"PeriodicalIF":9.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid Tuberculosis Depicted by 18 F-FAPI PET/CT.","authors":"Yuhua Wang, Lei Zhang, Feifei Qiao, Wanchun Zhang","doi":"10.1097/RLU.0000000000005799","DOIUrl":"10.1097/RLU.0000000000005799","url":null,"abstract":"<p><p>Thyroid tuberculosis is a rare condition that is difficult to diagnose and may be suspected of being a malignant tumor. We report a case of thyroid tuberculosis in a 54-year-old woman that mimicked thyroid cancer on ultrasound, with a 18 F-FAPI PET/CT scan showing intense 18 F-FAPI uptake in the thyroid lobe, right neck lymph node, and celiac lymph nodes.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"423-424"},"PeriodicalIF":9.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arterial Occlusion in Takayasu Arteritis Detected as a Blood Pool Defect on 18 F-FDG Semiconductor PET/CT.","authors":"Masahiro Koyama, Yohji Matsusaka, Kaho Watanabe, Akira Seto, Ichiei Kuji","doi":"10.1097/RLU.0000000000005701","DOIUrl":"10.1097/RLU.0000000000005701","url":null,"abstract":"<p><strong>Abstract: </strong>A 75-year-old woman with Takayasu arteritis was referred to 18 F-FDG PET/CT due to elevated C-reactive protein in her laboratory data. FDG PET/CT with semiconductor detectors revealed no uptake in the arterial walls, suggesting active inflammation. However, the blood pool uptake in the proximal portion of the left subclavian artery was defective, suggesting arterial occlusion. Magnetic resonance angiography revealed complete occlusion of the left subclavian artery. Ultrasonography showed the reverse flow of the left vertebral artery. Semiconductor PET can visualize the blood pool defects of the intra-arterial uptake in the arterial branches from the aorta.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"440-441"},"PeriodicalIF":9.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatostatin Receptor-Directed Theranostics in Esthesioneuroblastoma.","authors":"Yingjun Zhi, Sebastian E Serfling, Daniel Groener, Philipp E Hartrampf, Takahiro Higuchi, Matthias Scheich, Stephan Hackenberg, Andreas K Buck, Joachim P Steinbach, Rudolf A Werner, Konrad Klimek, Marinela Augustin","doi":"10.1097/RLU.0000000000005717","DOIUrl":"10.1097/RLU.0000000000005717","url":null,"abstract":"<p><strong>Background: </strong>We aim to report on somatostatin receptor (SSTR)-targeted molecular imaging and therapy in patients with advanced esthesioneuroblastoma (ENB).</p><p><strong>Patients and methods: </strong>Five patients with ENB [Kadish stage D in 5/5 (100%); Hyams grade 2 in 2/5 (40%), grade 3 in 2/5 (40%), undetermined in 1/5 (20%)] underwent SSTR-directed PET/CT. We quantified SSTR-avid tumor volume (TV), maximum SUV (SUV max ), and target-to-background ratios (TBR). Based on imaging, peptide receptor radionuclide therapy (PRRT) along with dosimetry was also conducted. We recorded nephrotoxicity and hematotoxicity, including estimated glomerular filtration rate (eGFR), hemoglobin, leukocytes, and thrombocytes at baseline and after the last treatment cycle. We determined adverse events following Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Response and progression-free survival (PFS) was also evaluated.</p><p><strong>Results: </strong>All 5 patients were rated positive on SSTR-PET/CT. On a lesion-based level, we identified 32 SSTR-avid tumor sites with a median TV of 11.7±10.8 and SUV max of 24.3±12.8. TBR was 19.8±9.7, indicating excellent image contrast. After median 4 (range, 2-6) cycles with a median of 7.7 GBq per cycle per patient, we observed no CTCAE grade 3 or 4 toxicity for leukocytes and thrombocytes and no significant CTCAE events for renal function. One patient (20%), however, developed reversible grade 3 anemia. Up to 11.8 Gy in tumor lesions were achieved. Partial response was recorded in 3/5 (60%), stable disease in 1/5 (20%), and progressive disease in 1/5 (20%). The median PFS was 29 weeks.</p><p><strong>Conclusions: </strong>SSTR-directed PET provided high image contrast in ENB, suggesting good read-out capabilities in this tumor type. PRRT was also feasible, along with an acceptable safety profile, thereby rendering SSTR-targeted theranostics a potential treatment option in advanced disease.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"363-367"},"PeriodicalIF":9.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detectability of Al 18 F-NOTA-HER2-BCH PET for Nodal Metastases in Patients With HER2-Positive Breast Cancer.","authors":"Xiaoyi Guo, Jiayue Liu, Shiyu Lin, Xinyu Gui, Jin Ding, Teli Liu, Nina Zhou, Suping Li, Hua Zhu, Zhi Yang","doi":"10.1097/RLU.0000000000005686","DOIUrl":"10.1097/RLU.0000000000005686","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to compare Al 18 F-NOTA-HER2-BCH and 18 F-FDG for detecting nodal metastases in patients with HER2-positive breast cancer on PET/CT.</p><p><strong>Patients and methods: </strong>In this retrospective study, 62 participants with HER2-positive breast cancer underwent both Al 18 F-NOTA-HER2-BCH and 18 F-FDG PET/CT. Participants were pathologically confirmed as HER2-positive (IHC 3+ or IHC 2+ with gene amplification on FISH). Three independent readers visually assessed uptake of tracers on imaging. Furthermore, the diagnostic accuracy of nodal metastases was assessed using c-statistics. The lesion uptakes were quantified by SUV max and target-to-background ratio (TBR) and compared using the general linear mixed model.</p><p><strong>Results: </strong>The findings showed nodal metastases in 33 (53%) participants, including 45% only with regional nodal metastasis and 55% with nonregional nodal metastasis. On per-patient level, the sensitivity and specificity of Al 18 F-NOTA-HER2-BCH and 18 F-FDG based on the majority reads were 0.97, 0.97, and 0.85, 0.77, respectively. Five participants were visualized only on Al 18 F-NOTA-HER2-BCH. Seven participants with high uptake only on 18 F-FDG PET/CT were confirmed to be inflammatory uptake by pathological results and later imaging follow-up. On per-lesion level, Al 18 F-NOTA-HER2-BCH PET/CT detected more axillary (98.8% vs 70.2%), extra-axillary (100% vs 61.7%), and nonregional (99.1% vs 67.0%) lymph nodal metastases than 18 F-FDG PET/CT. Additionally, Al 18 F-NOTA-HER2-BCH PET/CT detected more nodal metastases small than 10 mm than 18 F-FDG PET/CT (198 vs 125, 99.5% vs 62.8%). The median SUV max and TBR of regional or nonregional nodal metastases at Al 18 F-NOTA-HER2-BCH were all higher than those on 18 F-FDG (range of median SUV max , 8.0-11.4 vs 2.3-5.6; P range, <0.001-0.007; range of median TBR, 7.3-16.3 vs 2.9-5.3; P range, <0.001). No adverse reactions related to imaging agents were observed in all participants.</p><p><strong>Conclusions: </strong>Al 18 F-NOTA-HER2-BCH PET/CT detected more regional and nonregional lymph nodal metastases in patients with HER2-positive breast cancer than on 18 F-FDG PET/CT, especially for lesions small than 10 mm.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"381-387"},"PeriodicalIF":9.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18 F-FDG PET/CT of Intrapulmonary Schwannoma Mimicking Lung Cancer in the Right Lower Lobe.","authors":"Zhiying Liang, Wei Li","doi":"10.1097/RLU.0000000000005590","DOIUrl":"10.1097/RLU.0000000000005590","url":null,"abstract":"<p><p>A 53-year-old woman was found to have a soft tissue mass in the right lower lung lobe on chest CT, raising suspicion of lung cancer. For staging, 18 F-FDG PET/CT was performed, which demonstrated intense tracer uptake in the mass (SUV max , 14.6). Subsequently, surgical excision was undertaken, and histopathological examination of the resected specimen confirmed the diagnosis of a schwannoma.</p>","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"e294-e296"},"PeriodicalIF":9.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}